Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia

Hind I Fallatah, Hisham O Akbar, Yousif A Qari, Hind I Fallatah, Hisham O Akbar, Yousif A Qari

Abstract

Background/aim: Autoimmune hepatitis (AIH) is a common cause of end-stage liver disease worldwide. It is a disease prevalent in children and adults, with female predominance and variable clinical presentations. AIH has favorable responses to steroids and immunomodulators. Diagnosis of AIH is based on clinical and laboratory criteria, as suggested by the International Autoimmune Hepatitis Group. Data on the disease pattern of AIH from the Middle East countries is scarce.

Materials and methods: In this retrospective analysis, we studied clinical and laboratory features, immunological data, radiological findings, liver biopsy findings and response to therapy in patients with AIH from the hepatology clinics of King Abdul Aziz, University Hospital, Jeddah, from 1994 to 2008.

Results: We diagnosed 41 patients with AIH, and 33 were included in the analysis. The mean age was 32.3 years, with female predominance of 75.7%. De-compensated cirrhosis at presentation was found in 45.5% of the patients. Acute hepatitis was associated with significantly higher levels of the serum ALT and bilirubin (P=0.001 and P=0.03, respectively). All our patients had type 1 AIH. Treatment with prednisolone and azathioprine resulted in complete or partial remission in majority of the patients (54.8%). However, patients with advanced disease showed a poorer response to treatment (P=0.016). Six patients with poor compliance had relapse of AIH. Two patients had a flare of the disease during pregnancy, and they responded well with prednisolone. The longest follow-up was 14 years and the shortest was 2 months. Four patients died from liver disease.

Conclusion: AIH patients in Saudi Arabia are likely to present with advanced disease at a young age and would have a poorer response to therapy as compared with patients in other countries worldwide.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Age in relation to de-compensated cirrhosis

References

    1. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am. 1996;80:973–94.
    1. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051–7.
    1. Bellomo-Brandão MA, Costa-Pinto EA, de Tommaso AM, Hessel G. Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients. Arq Gastroenterol. 2006;43:45–9.
    1. Miyake Y, Iwasaki Y, Takaki A, Kobashi H, Sakaguchi K, Shiratori Y. Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med. 2007;46:1945–9.
    1. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–8.
    1. Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol. 2005;5:27.
    1. Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, et al. Meeting Report, International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005.
    1. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.
    1. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.
    1. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:202–14.
    1. Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med. 2008;99:549–68.
    1. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.
    1. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62–9.
    1. Bashawri LA, Fawaz NA, Ahmed MS. Prevalence of seromarkers of HBV and HCV among blood donord in eastern Saudi Arabia. Clinical lab Hematol. 2004;26:225–8.
    1. Hazmi EL. Prevalence of HBV, HCV, HIV-I,II infections among blood donors in a teaching hospital in the central region of Saudi Arabia. Saudi Med J. 2004;25:26–33.
    1. Abdo AA. Clinical presentation, response to therapy, and predictors of fibrosis in patients with autoimmune hepatitis in Saudi Arabia. Saudi J Gastroenterol. 2006;12:73–6.
    1. Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, et al. Liver transplantation for autoimmune hepatitis: A single-center experience. Transplant Proc. 2007;39:1166–70.
    1. Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, et al. Type 1 autoimmune hepatitis: Patterns of clinical presentation and differential diagnosis of the acute type. Q J Med. 2004;97:407–12.
    1. Czaja A, Freese D. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–97.
    1. Huang H, Huang Y, Wu J, Tsay S, Huo T, Wang Y, et al. Characteristics of autoimmune hepatitis in Taiwan: The 11 years’ experiences of a medical center. Zhonghua Yi Xue Za Zhi (Taipei) 2002;65:563–9.
    1. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.
    1. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003.
    1. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis. Am J Gastroenterol. 2008;103:3063–70.
    1. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828–35.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe